ANZCTR search results

Improvements in treatment results for adult acute myeloid leukaemia (AML) over the past 15 years have come mainly from the use of higher dose intensity of existing chemotherapy agents, rather than from the introduction of new classes of anti-leukaemic drugs. Increased dose intensity protocols have included the use of chemo-radiotherapy, Early intensification of treatment using the most effective drugs available for AML is a highly effective strategy, possibly through rapid elimination of potentially drug-resistant cells. Hypothesis; a) That Palifermin, given as three doses of 60 µg/kg per day IV before and three doses after ICE chemotherapy, will reduce the incidence of grades 3 and 4 oral mucositis. b) That an increase in the dose intensity of Idarubicin given early during the initial treatment of AML will result in significantly greater anti-leukaemic activity, and that this dose escalation of Idarubicin in consolidation treatment following induction therapy with high dose Cytarabine will achieve improved leukaemia-free survival.

The proposed research project will investigate whether high-intensity, community-based exercise programs performed once a week are sufficient to maintain or improve a variety of subjective and objective outcomes including the physical function, balance, independence and program adherence of older adults post-discharge from a Day Rehabilitation Centre (DRC). The â¿¿once a weekâ¿¿ exercise intervention will be directly compared with â¿¿twice a weekâ¿¿ exercise, and with usual care for a period of 12 weeks post discharge. Participants will be followed up at the end of the intervention period and at 12 months post discharge from the DRC. The cost effectiveness of the interventions will also be determined.

Intervention and 1-year follow-up have been completed. Further 2-year follow-up is in progress.

The study aims to determine if supplementation with fish oils or the vitamin coenzyme Q10, or a combination of both, will lead to beneficial effects on blood pressure and heart disease risk in patients with renal impairment. Heart disease is one of the main causes of death in Australia. People with renal impairment are at increased cardiovascular risk due to the coexistence of hypertension (high blood pressure), blood lipid abnormalities (blood fats) and increased inflammation. One approach may be to complement drug treatment of renal impairment with non-drug measures such as nutrition and lifestyle factors. In this regard, fish oils have great clinical potential in the treatment of renal impairment and its associated complications. Fish oils reduce blood pressure and improve blood vessel wall elasticity. They improve blood fats, reduce the tendency of blood to clot and reduce inflammation. Coenzyme Q10 is a vitamin that plays a critical role in cell function. It improves blood pressure, blood vessel and heart function, and glucose control.

Subjects randomly allocated to receive either active, aggressive diet and exercise program or simple information sheet only, for 4 months